NEW YORK (GenomeWeb News) – Beckman Coulter Genomics today said that three states have licensed its BRAF assay, expanding the availability of the test.

Pennsylvania, Maryland, and Rhode Island have granted clinical laboratory licenses to Beckman Coulter Genomics for the assay, which is CLIA certified. Massachusetts licensed the assay last year, and of the seven states that require licensures in addition to CLIA certification for certain tests to be offered there, Florida, California, and New York remain the only ones that have not licensed Beckman Coulter's BRAF assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.